

Marcie L Riches

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7303663/publications.pdf>

Version: 2024-02-01

43
papers

2,417
citations

430874

18
h-index

302126

39
g-index

53
all docs

53
docs citations

53
times ranked

3987
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 2022, 28, 48.e1-48.e10.	1.2	18
2	Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost. Transfusion and Apheresis Science, 2022, 61, 103303.	1.0	4
3	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplantation and Cellular Therapy, 2022, 28, 409.e1-409.e10.	1.2	26
4	Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study. Transplantation and Cellular Therapy, 2022, 28, 696.e1-696.e7.	1.2	7
5	Statistical Methods for Time-Dependent Variables in Hematopoietic Cell Transplantation Studies. Transplantation and Cellular Therapy, 2021, 27, 125-132.	1.2	8
6	Infectious Complications. , 2021, , 493-512.		0
7	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematology,the, 2021, 8, e185-e193.	4.6	271
8	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. Transplantation and Cellular Therapy, 2021, 27, 267.e1-267.e5.	1.2	6
9	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305.	1.4	85
10	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 591-599.	1.2	4
11	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplantation and Cellular Therapy, 2021, 27, 885-907.	1.2	12
12	Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. Transplantation and Cellular Therapy, 2021, 27, 1021.e1-1021.e5.	1.2	15
13	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649.	1.2	65
14	The new world. Current Opinion in Hematology, 2021, Publish Ahead of Print, 389-393.	2.5	1
15	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and Cellular Therapy, 2021, 27, 993.e1-993.e8.	1.2	4
16	<i>Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?</i>. Blood, 2021, 138, 2870-2870.	1.4	0
17	CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients. Blood, 2021, 138, 2829-2829.	1.4	4
18	The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study. Blood, 2021, 138, 2894-2894.	1.4	0

#	ARTICLE	IF	CITATIONS
19	MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT. <i>Blood</i> , 2021, 138, 2955-2955.	1.4	0
20	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury—Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2020, 3, e1918668.	5.9	40
21	Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2365-2371.	2.0	6
22	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
23	Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. <i>Blood</i> , 2020, 136, 137-139.	1.4	51
24	Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 858.	4.1	16
25	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
26	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	1.7	22
27	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	2.4	19
28	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	5.2	13
29	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	2.4	47
30	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 699-711.	2.0	11
31	Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1771-1779.	5.8	41
32	Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 955-964.	2.0	7
33	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. <i>Haematologica</i> , 2019, 104, 844-854.	3.5	13
34	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
35	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
36	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018, 53, 1434-1444.	2.4	8

#	ARTICLE	IF	CITATIONS
37	Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 797-805.	1.8	6
38	Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 165-171.	2.0	12
39	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1440-1448.	2.0	44
40	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	1.4	246
41	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016, 127, 1656-1665.	1.4	255
42	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. <i>Blood</i> , 2016, 127, 2427-2438.	1.4	403
43	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71